Trial Profile

A Phase Ib, Open Label, Single Dose Clinical Study to Evaluate the Safety and Therapeutic Effects of Infusion of MNV-201 in Patients With Low Risk Myelodysplastic Syndrome

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 20 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Sep 2024 According to a Minovia Therapeutics media release, the company have safely dosed two MDS patients enrolled in an ongoing study under the Israeli Ministry of Health.
26 Sep 2024 According to a Minovia Therapeutics media release, the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for MNV-20. The IND supports the initiation of a Phase Ib dose exploration clinical trial of MNV-201 in patients with Low Risk Myelodysplastic Syndrome (MDS). The study is expected to enroll at least three patients each in the low, medium and high dose cohorts, and up to a total of 15 patients in total.
19 Jun 2024 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com